Abstract

To develop evidence generation strategic insights and lessons for ultra orphan drugs based on mistakes identified by NICE during Highly Specialized Technology (HST) assessments.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
OP19 Does The HST Represent A Best Practice Model For Ultra-Orphan HTA?
Richard Macaulay ... Lok Wan Liu
International Journal of Technology Assessment in Health Care | VOL. 35
Richard Macaulay, et. al.Richard Macaulay ... Lok Wan Liu
01 Jan 2019
PRO117 ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018
T Thorat ... J.L Rubin
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 22
T Thorat, et. al.T Thorat ... J.L Rubin
01 Nov 2019
PRO108 ANALYSIS OF NICE AND US ICER HTA OUTCOMES FOR ULTRA-ORPHAN MEDICINAL PRODUCTS
M Dusza ... M Toumi
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 22
M Dusza, et. al.M Dusza ... M Toumi
01 Nov 2019
PMU9 DO NICE APPRAISAL PROCESSES REWARD INNOVATIVE AND CURATIVE THERAPIES? AN ASSESSMENT OF CURRENT AND POTENTIAL FUTURE TECHNOLOGY APPRAISALS FOR RARE DISEASES
B Miller ... B Maru
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 22
B Miller, et. al.B Miller ... B Maru
01 May 2019
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
Generating utilities for the CS-Base: a novel, generic, and patient-centered health-outcome measure
Xin Zhang ... Paul Fm Krabbe
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Xin Zhang, et. al.Xin Zhang ... Paul Fm Krabbe
06 Jul 2024
Do Behavioral Characteristics Influence the Breast Cancer Diagnosis Delay? Evidence From French Retrospective Data
Christine Le Clainche ... Jean-Christophe Vergnaud
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Christine Le Clainche, et. al.Christine Le Clainche ... Jean-Christophe Vergnaud
06 Jul 2024
Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey
Gordon G Liu ... Huajie Jin
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Gordon G Liu, et. al.Gordon G Liu ... Huajie Jin
06 Jul 2024
Valuation of Multi-Dimensional Health States With a Bolt-On: Is There a Shortcut?
Zhihao Yang ... Nan Luo
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Zhihao Yang, et. al.Zhihao Yang ... Nan Luo
06 Jul 2024
View more papers